Ucb S.a. · EURONEXT:UCB
Ucb — 44th Annual J.P. Morgan Healthcare Conference 2026
16 slides from Ucb's conference presentation, Jan 14, 2026
Slide 1: Turning Strategy into Results
Turning Strategy into Results Jean-Christophe Tellier, CEO 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-loo
Slide 3: Performance Driven by Strength
by Strength Performance Driven 3 Proprietary and Confidential Property of UCB
Slide 4: Strong Foundation, Growth Drivers
Strong Foundation 5 Growth Drivers First and only IL-17A & IL-17F inhibitor Est. Strong Patent Protection** 2037 Growth Global Legacy of Sustainability Listed on First agent for anti-AChR+ & anti-MuSK+ gMG Engine Built biopharma scientific as business Euronext company excellence approach Brussels on
Slide 5: Agility and Resilience Supporting Growth
Continuous investment in Agility and differentiated innovation and Investment in diverse platforms & modalities Resilience patient biology Supporting Growth Proprietary Property of UCB Biomanufacturing expansion to ~$5bn U.S. investment in support current portfolio and future mammalian antibody plan
Slide 6: Sustained Momentum: 2025 Outlook
Annual Revenue adjusted EBITDA Margin 2025 Outlook Upgraded on >24% Powered by the five growth drivers, with BIMZELX® exceeding Sustained >€7.6bn >700 expectations through strong demand and favorable U.S. payer mix Momentum bps Proprietary Property of UCB €6.15bn >31%* Disciplined execution to susta
Slide 7: Strategy in Action
Strategy in Action 7 Proprietary and Confidential Property of UCB
Slide 8: UCB's Long-term Value Creation
UCB’s Long-term Value Creation Proprietary Property of UCB Focused Patient-Centric Scaling Impact Innovation & Approach Anchored in Through Execution Scientific Disease Biology Excellence Excellence UCB – 44th Annual J.P. Morgan Healthcare Conference | 14th January 2026 8
Slide 9: Differentiated Innovation in Action: TK2 deficiency
first and only approved* treatment for adult and pediatric patients Thymidine Kinase 2 deficiency** Differentiated Innovation in Action Deep disease-biology insight targeting high unmet need Proprietary Property of UCB Strong ecosystem partnerships with approvals supported by real-world evidence alo
Slide 10: Differentiated Innovation in Action: Multispecific antibody in atopic dermatitis
first and only IL-13 and IL-17A & IL-17F inhibitor Differentiated Innovation in Multispecific antibody addressing Action disease heterogeneity beyond Th2 biology Proprietary Property of UCB Mechanism of AD pathogenesis1,# Encouraging 12-week skin- clearance with an acceptable risk- benefit profile,
Slide 11: Differentiated Innovation in Action: Bepranemab in Alzheimer's
Targeting pathological tau to transform the treatment of early Alzheimer's disease Differentiated Innovation in Tau is the next frontier in Action Alzheimer’s disease with disease care shifting to earlier intervention and biology-led treatment Proprietary Property of UCB Bepranemab is the first-ever
Slide 12: Execution Excellence in Action: bimekizumab approvals
approved in 50 countries …by 21 Regulatory Authorities …across 5 indications Execution Excellence in Action Proprietary Property of UCB bimekizumab indication expansion • Pediatric (PSO, HS, JIA) • Palmoplantar Pustulosis (PPP) *EC approval extends to European Economic Area (EEA) countries of Icelan
Slide 13: BIMZELX Strategic Access Expansion
BIMZELX Strategic Access Expansion 2026 Execution Excellence in Action +36M ** Proprietary Property of UCB 25% increase vs. 2025 Total BIMZELX Patients (R3M)* 80% Patient adoption outpacing analogues – all indications ≥ & vast majority of Medicare & Medicaid patients M10 M11 M12 M13 M14 M15 M16 M17
Slide 14: Execution Excellence in Action
>1.2M patients Most Recent approval in China (December 2025) Execution Excellence in Action Approved by 12 regulatory authorities Robust, Consistent, Flexible Proprietary Property of UCB Approved by 10 regulatory authorities Potent, Sustained, Empowered Positive Phase 3 in CDKL5 Deficiency Disorder
Slide 15: A Position of Strength Driving Growth for a Decade+
Differentiated innovation translating science into new and targeted therapies A position of Strength Proprietary Property of UCB Executing with agility and resilience to deliver future … Driving Growth for a solutions for patients, this decade and beyond Decade+ Purpose-led performance, creating lon
Slide 16: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB
UCB — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix